Analysts Set Sucampo Pharmaceuticals, Inc. (SCMP) Target Price at $20.00

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) have been assigned an average recommendation of “Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.00.

Several equities analysts recently commented on SCMP shares. Maxim Group reaffirmed a “buy” rating and set a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. BidaskClub lowered shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Mizuho reaffirmed a “hold” rating and set a $12.00 target price on shares of Sucampo Pharmaceuticals in a report on Wednesday, November 1st. Instinet started coverage on shares of Sucampo Pharmaceuticals in a report on Tuesday, December 19th. They set a “buy” rating and a $43.00 target price on the stock. Finally, B. Riley increased their target price on shares of Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, December 6th.

Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) remained flat at $$18.00 during trading hours on Wednesday. The company’s stock had a trading volume of 303,068 shares, compared to its average volume of 2,770,000. The stock has a market cap of $839.46, a P/E ratio of -5.37, a price-to-earnings-growth ratio of 5.06 and a beta of 1.38. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37.

In related news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the transaction, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.13% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its position in Sucampo Pharmaceuticals by 4.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 790 shares during the period. Thrivent Financial For Lutherans boosted its position in Sucampo Pharmaceuticals by 11.3% during the 2nd quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 1,550 shares during the period. Ameriprise Financial Inc. boosted its position in Sucampo Pharmaceuticals by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 131,790 shares of the biopharmaceutical company’s stock valued at $1,384,000 after buying an additional 1,690 shares during the period. Teachers Advisors LLC boosted its position in Sucampo Pharmaceuticals by 2.9% during the 2nd quarter. Teachers Advisors LLC now owns 68,499 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 1,953 shares during the period. Finally, Voya Investment Management LLC boosted its position in Sucampo Pharmaceuticals by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 13,411 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 2,477 shares during the period. 67.09% of the stock is owned by institutional investors and hedge funds.

WARNING: “Analysts Set Sucampo Pharmaceuticals, Inc. (SCMP) Target Price at $20.00” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://stocknewstimes.com/2018/02/17/analysts-set-sucampo-pharmaceuticals-inc-scmp-target-price-at-20-00.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply